HTF Market Intelligence has released a comprehensive 143-page study on the global genetic engineering market, projecting it will grow from $10 billion in 2025 to $28 billion by 2032 at a compound annual growth rate (CAGR) of 14.2%. The market is segmented by type—including gene therapy, CRISPR gene editing, genetically modified crops, and synthetic biology—and by application such as medicine, agriculture, and industrial biotech. Key players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, and others. North America is the dominant region, while Asia-Pacific is the fastest-growing. Market drivers include advances in genome editing, demand for sustainable agriculture, and evolving regulatory frameworks. Challenges include ethical concerns, high costs, intellectual property disputes, and environmental risks. The report includes detailed analysis of market segments, competitive landscape, five forces, and PESTLE factors across global regions.

Bio-Rad Laboratories has expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies to include specificities for pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and emicizumab (Hemlibra). The company has also introduced a new Human IgM-FcSpyCatcher reagent to its SpyCatcher line, enabling rapid generation of pentameric and hexameric IgM formats without additional cloning. These tools support robust bioanalytical assays for pharmacokinetic and anti-drug-antibody studies, aiding in therapeutic drug level monitoring for innovator and biosimilar products. The new reagent is fully compatible with Bio-Rad’s recombinant HuCAL antibodies and has been validated in ELISA, western blotting, and precipitation workflows. The products are approved for in vitro research and commercial in vitro testing services, supporting preclinical and clinical development, biosimilar programs, and patient monitoring.

The global market for antibody ELISA kits used in diagnosing tropical infectious diseases is projected to grow from USD 2.39 billion in 2024 to USD 4.41 billion by 2034, representing a CAGR of 6.32% from 2025 to 2034. Asia Pacific dominates the market with a 33.2% revenue share in 2024 and is expected to grow at a CAGR of 6.51%, while the Middle East & Africa is projected to be the fastest-growing region. Key drivers include rising disease surveillance, public health investments, and the adoption of advanced diagnostic technologies such as AI-enhanced ELISA platforms. The dengue segment holds the largest market share by disease type, with the Zika virus segment expected to grow at the fastest rate. The IgM segment dominates by antibody type, while serum is the leading sample type. The diagnostic laboratories segment is the largest end user, and distributors/wholesalers dominate the distribution channel. Recent developments include new ELISA kits from InBios International, Agdia, and Panadea Diagnostics focused on improving accuracy and enabling point-of-care or field use, particularly in resource-limited settings.

The global market for antibody ELISA kits used in diagnosing tropical infectious diseases is projected to grow from USD 2.54 billion in 2025 to USD 4.15 billion by 2033, at a CAGR of 6.32%. Growth is driven by rising disease prevalence, demand for rapid diagnostics, and expansion of healthcare infrastructure, especially in rural and low-income regions. The dengue segment dominates by disease type due to high transmission rates, while IgM-based kits lead by antibody type for early infection detection. Serum samples and indirect ELISA technology hold the largest market shares by sample and technology type, respectively. Diagnostic laboratories are the primary end-users, with distributors/wholesalers leading in distribution. Asia Pacific holds the largest market share, with India, Indonesia, and the Philippines showing strong adoption. The Middle East & Africa region is expected to grow rapidly due to vector-borne disease burdens and increasing access to affordable diagnostics. On July 21, 2025, the Indian Council of Medical Research (ICMR) launched an advanced IgM-based ELISA kit for Chikungunya with 95% accuracy, validated by the U.S. CDC, and is seeking technology transfer and commercialization partners.

HTF MI has released a comprehensive global market study on the hemoglobin analyzer industry, projecting steady growth from 2025 to 2031. The market was valued at USD 6706.95 million in 2024 and is expected to reach USD 9698.7 million by 2031, with a CAGR of 5.41%. The market is segmented by product type (handheld, benchtop/automatic, semi-automatic), application (blood glucose monitoring, control, diabetes diagnosis), and end-user (hospitals, labs, home care, blood banks, research). Key drivers include rising anemia screening in maternal and child health, chronic disease management, and point-of-care testing. Market opportunities lie in national anemia programs, rural outreach, and integration with mHealth. Challenges include budget constraints, supply chain issues, and calibration difficulties. North America is the dominant region, while Asia–Pacific is the fastest-growing. The report includes a detailed analysis of key players, competitive landscape, and five forces/PESTLE framework.